Lbmc Investment Advisors LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lbmc Investment Advisors LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 345 shares of the medical research company’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Campbell & CO Investment Adviser LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter worth about $382,000. Nomura Holdings Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $15,005,000. Vontobel Asset Management Inc. boosted its position in Thermo Fisher Scientific by 16.9% during the 4th quarter. Vontobel Asset Management Inc. now owns 946,099 shares of the medical research company’s stock worth $526,890,000 after acquiring an additional 136,963 shares during the period. Veritas Asset Management LLP raised its stake in shares of Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after acquiring an additional 697,383 shares in the last quarter. Finally, Symmetry Investments LP bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $5,839,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on TMO. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Barclays reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. Morgan Stanley increased their price target on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Robert W. Baird increased their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, Wells Fargo & Company assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $653.72.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $0.93 during mid-day trading on Tuesday, hitting $597.92. The company’s stock had a trading volume of 173,919 shares, compared to its average volume of 1,467,324. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The stock has a market cap of $228.24 billion, a price-to-earnings ratio of 38.25, a PEG ratio of 3.88 and a beta of 0.77. The business’s fifty day moving average is $609.35 and its two-hundred day moving average is $582.90.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter in the prior year, the firm posted $5.15 earnings per share. The company’s revenue was down 1.4% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Activity

In other news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,860,920.55. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,084 shares of company stock valued at $14,094,292 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.